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Longitudinal changes 
in reproductive hormones 
through the menopause transition 
in the Avon Longitudinal Study 
of Parents and Children (ALSPAC)
Ana Goncalves Soares 1,2*, Fanny Kilpi 1,2, Abigail Fraser 1,2,3, Scott M. Nelson 3,4, 
Naveed Sattar 5, Paul I. Welsh 5, Kate Tilling 1,2,3,6 & Deborah A. Lawlor 1,2,3,6
We characterised changes in reproductive hormones—LH, FSH, SHBG and AMH—by chronological age 
and time around the menopause (reproductive age) in mid-life women and explored their associations 
with lifestyle and reproductive factors. We used data from 1608 women from a UK cohort who had 
repeat hormone measures and experienced a natural menopause. Multilevel models were used to 
assess: (i) changes in hormones (outcomes) by reproductive age and chronological age (these age 
variables being the key exposures) and (ii) associations of body mass index (BMI), smoking, alcohol 
intake, parity and age at menarche with changes in hormones by reproductive age. Both LH and 
FSH increased until ~ 5 and 7 years postmenopause, respectively, after which they declined, but 
not to premenopausal levels. SHBG decreased slightly until ~ 4 years postmenopause and increased 
thereafter. AMH decreased markedly before menopause and remained low subsequently. For all 
hormones, the best fitting models included both reproductive and chronological age. BMI, smoking 
and parity were associated with hormone changes; e.g., higher BMI was associated with slower 
increase in LH and FSH and decrease in AMH. Reproductive and chronological age contribute to 
changes in LH, FSH, SHBG and AMH across mid-life in women, and BMI, smoking and parity are 
associated with these hormone changes.
Cross-sectional and longitudinal studies suggest that age at menopause is associated with numerous health 
outcomes, including inverse associations with adverse cardiometabolic, skeletal and mental health  outcomes1–4. 
Among other factors, it is assumed that these associations might be driven, at least to some extent, by the 
hormonal changes that occur around the time of the menopausal  transition5–7, but these changes are not well 
characterised for some reproductive hormones.
There is evidence that levels of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) increase 
with reproductive age, particularly from 2-years before to 2-years after the final menstrual period (FMP), and 
thereafter remain at the same high  levels8–10. Most longitudinal studies suggest that sex-hormone binding globulin 
(SHBG) levels decrease during the menopausal  transition11–13, though one study showed an  increase14. Anti-
Müllerian hormone (AMH) declines before the FMP and has been extensively explored as a predictor of time 
to  menopause15–17. Whilst these studies report changes in AMH levels with chronological age, few longitudinal 
studies have described changes of AMH levels with reproductive age. Where this has been described, results 
suggest that the pattern of decline is not uniform between women, and varies depending on pre-menopausal 
AMH levels, with women who had higher AMH level 20 years before the FMP having a slower decline between 
20 and 15 years before the FMP and reversing to a faster decline in the last 5 years before the  menopause15. Most 
studies with repeatedly assessed hormone data tend to have small sample sizes and do not compare whether 
change over time is best predicted by reproductive or chronological ageing.
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Several studies have examined associations of lifestyle and reproductive factors with single measure concen-
trations of LH, FSH, SHBG and  AMH18–24. Fewer longitudinal studies have assessed how lifestyle (e.g. body mass 
index (BMI), smoking, alcohol intake, physical activity) and earlier reproductive factors (e.g. parity and age at 
menarche) are associated with hormonal changes. In Supplementary Table 1 we summarise the seven studies 
we identified in a literature search that explore the associations of lifestyle and reproductive factors with change 
in reproductive hormones in women in mid-life8,9,16,25–28.
The aims of this study were to (1) characterise the patterns of change in FSH, LH, SHBG, and AMH through 
the menopausal transition; (2) determine whether these change patterns are associated with reproductive age (i.e. 
time around the final menstrual period) or chronological age, or both; and (3) explore associations of lifestyle 
and reproductive factors with these hormone patterns.
Methods
Participants. Data from the Avon Longitudinal Study of Parents and Children (ALSPAC) were used. All 
pregnant women resident in Avon, a former county comprising the area surrounding the city of Bristol, United 
Kingdom (UK), who had an estimated delivery date between 1 April 1991 and 31 December 1992 were eligible 
for the study, and 14,451 pregnancies were  enrolled29. Pregnant women originally resident in Avon but migrating 
out of the catchment area prior to delivery were excluded, unless they had completed the questionnaire sched-
uled for the third trimester of pregnancy. Full details of recruitment, follow-up and data collection for these 
women, as well as their children and partners, have been reported  elsewhere29,30, and the study website contains 
details of all the data that are available through a fully searchable data dictionary and variable search tool (http://
www.brist ol.ac.uk/alspa c/resea rcher s/our-data/). Ethical approval for the ALSPAC Study was obtained from the 
ALSPAC Law and Ethics Committee and UK National Health Service Research Ethics Committees. All proce-
dures performed were in accordance with the ethical standards of the ALSPAC Law and Ethics. Participants 
provided written informed consent regarding their participation.
Approximately 18 years after enrolment in ALSPAC (where enrolment was during the “index” pregnancy), 
all mothers still engaged with ALSPAC (N = 11,264) were invited to join this study, which included detailed 
clinic assessments repeated up to four  times29,31. Women who were pre- or perimenopausal at the first clinic 
assessment and aged 40 years or over, and therefore likely to make a transition through one or more stages of the 
menopausal transition in the following 5 years, were invited to attend the further three clinic  assessments29. The 
assessments were completed as follows: first, between 2009 and 2011 when women were [median (IQR)] aged 
48 (45; 51); second, about 2.5 years later, between 2011 and 2013 when aged 51 (48, 54); third, approximately 
1.3 years later, at 2013–2014 when aged 52 (49, 55); and fourth, about 1 year later, at 2014–2015 when aged 53 
(50, 56). Women were included in the specific analyses presented here if they attended at least one of these clinic 
assessments, had data on reproductive hormones and had experienced the menopause (at least 12 months with 
no menstrual periods) by the last clinic assessment. As we were interested in patterns of change in hormone levels 
(our outcomes) related to a natural menopausal transition, we excluded women who had experienced any of the 
following: hysterectomy, oophorectomy, endometrial ablation, or radio- or chemotherapy related to reproduc-
tive organs. Observations from women reporting using hormonal contraception or hormone replacement were 
censored at the measurement before starting hormones. Following these exclusions, our analysis included 1,608 
women, with 4,037 measures (Fig. 1).
Assessments of reproductive hormones. In all four assessments, blood samples were taken following 
a standardised protocol. After collection, the blood was immediately centrifuged and frozen at − 80 °C, and the 
samples were assayed within 3 years of storage with no previous freeze–thawing cycles. Levels of four repro-
ductive hormones were assessed: FSH, LH, SHBG, and AMH. AMH was measured using the fully automated 
Elecsys AMH Plus  immunoassay32. All other hormones were measured with a Roche Elecsys modular analytics 
Cobas e411 using an electrochemiluminescence immunoassay using the manufacturers calibrators and quality 
control material.
Assessments of factors that might influence changes in reproductive hormones in mid-life. At 
each clinic assessment, women were asked a detailed set of questions about their menstrual cycle, the date of 
their last menstrual period and the frequency and regularity of their menses, as well as lifestyle information and 
collection of anthropometric  measures31. For each woman, reproductive age was calculated by subtracting the 
date of her FMP from the date which she attended the clinic assessment. Reproductive age was represented in 
years before and after the date of her menopause, which was the date of the menstrual period reported before 
the absence of menses for 12 or more months; hence 0 is the date of her FMP, − 1 would be 1 year before that 
date and + 1, 1 year after that date. Therefore, reproductive age was only defined for women who went through 
the menopause during the study period. Stages of Reproductive Aging Workshop (STRAW) criteria were used 
to categorise women into one of three mutually exclusive reproductive stages at each clinic assessment: (i) pre-
menopausal (late reproductive age); (ii) menopausal transition; and (iii) postmenopause (irrespective of the 
years since menopause)31,33.
As we wanted to explore prospective associations of risk factors with reproductive hormone patterns, we used 
measures for BMI, smoking status and alcohol intake that were obtained at, or before, the first clinic assessment. 
Information on recalled age at menarche, number of previous pregnancies, age at first pregnancy and maternal 
education were obtained around the time of recruitment to the study (mean age 28.3, SD 4.8), with information 
from subsequent questionnaires used to update parity (last data obtained at a similar time to the first mid-life 
clinic assessment when women were mean 48.4 (SD 4.4) years old).
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Statistical analyses. The analyses were performed in the software Stata 15.1 (Statacorp, College Station, 
TX, USA) and the software MLwiN 3.04, accessed from within Stata using runmlwin34. We log-transformed all 
the hormones to obtain approximately normally distributed residuals in regression models. We then back trans-
formed results for ease of interpretation. We used multilevel models to examine associations of each hormone 
with chronological and reproductive ageing, allowing for repeated measures within women. The multilevel mod-
els include all women with at least one hormone measure, under the missing at random (MAR) assumption. We 
used fractional polynomials to assess non-linear  associations35. More details on fractional polynomials are pre-
sented in supplementary material. The power functions in the models varied (details available in supplementary 
material). Hormone levels were modelled against reproductive age alone, chronological age alone and with both 
time scales in the model; in the latter, age was centred at 51 years (mean age in our study). Given time has to be 
greater than zero when using fractional polynomials, a constant of 5 was added to time since FMP (as the lowest 
time since FMP was − 4.7 years). Model fit was assessed using Akaike Information Criterion (AIC) and Bayesian 
Information Criterion (BIC). Average predicted means for each reproductive hormone by reproductive age and 
chronological age were calculated from the multilevel models.
To explore whether hormone levels differed by categories of risk factors, multilevel models (as above) for 
each hormone were fitted with an interaction term between the risk factor and reproductive age. The risk factor 
categories used in these analyses were: BMI (normal/underweight (≤ 24.9 kg/m2), overweight (25.0–29.9 kg/
m2), obese (≥ 30.0 kg/m2)); smoking (never, past, current); alcohol intake (never or ≤ 4 times/month, 2–3 times/
week, ≥ 4 times/week), age at menarche (early (≤ 11 years), average (12–14 years), late (≥ 15 years)), and parity 
(1, 2, 3, ≥ 4 pregnancies). These analyses were adjusted for age, educational achievement and other potential 
confounders. The latter varied by which factor was being associated with the outcomes (full details in supple-
mentary material). Average predicted means for each reproductive hormone by reproductive age were calculated 
for each category of the risk factors.
We performed post hoc analysis exploring whether hormone changes by reproductive age differed by age at 
menopause. We divided age at menopause into quintiles and fitted multilevel models including an interaction 
term between the quintiles of age at menopause and reproductive age.
Dealing with missing data. There were missing data on some of the potential risk factors and confound-
ers, in particular for alcohol (31%) and smoking (8.5%) (Supplementary Table 2). Missing data were imputed 
using multivariable multiple imputation with chained equations, performed using the mice command in  Stata36. 
We used 50 imputed data sets and included all variables included in any models (including the time-varying 
hormone measures) in the imputation models. Data on smoking status and alcohol intake from questionnaires 
completed up to 7 years prior to the first mid-life clinic assessment were also used in the prediction models for 
missing risk factors.
Sensitivity analyses. To circumvent the possibility of influential outliers, we performed sensitivity analysis 
restricting the data at the 5th and 95th centiles of time since FMP (n = 1,552 women with 3,640 observations). To 
Figure 1.  Participant flow into analysis groups.
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explore the sensitivity of our results to including all women with at least one hormone measure we also repeated 
analyses only in women with 3 or 4 repeat measures (n = 818 women with 2,862 observations). We compared our 
main analyses (using multivariable imputation for missing risk factor or confounder values) to analyses includ-
ing only those with complete data on risk factors and confounders (n varying from 1,042 to 1,410 women with 
2,770 to 3,582 observations). Our main analyses can only include women who are known to have gone through 
the menopause, as this is required to calculate reproductive age. This might introduce selection bias, and to 
explore this, we compared patterns of change in hormone levels by chronological age in all women, irrespective 
of whether or not they had gone through the menopause (n = 3,493 women with 8,139 observations), to the 
main results for patterns of change by chronological age (i.e. in only those who had gone through the meno-
pause). An indicator variable of whether the woman experienced menopause (and therefore was included in the 
main analysis) or not (therefore excluded from the main analysis) was created. Since for those with unknown 
status of menopause the time since FMP could not be estimated, a constant of zero was used (i.e. we assumed 
those women to be premenopausal). The models for the sensitivity analyses were fitted with an interaction term 
between menopause (yes/no) and chronological age, adjusted for time since FMP.
We also performed post hoc sensitivity analysis using generalized estimating equations (GEE). GEE analyses 
assume a different pattern of missingness (missing completely at random—MCAR) than multilevel models and 
are more robust to the misspecification of the covariance structure. Additionally, using information from women 
with known and unknown date of menopause and with information on menopausal stages (n = 3,460 women with 
8,021 observations), we performed GEE analysis of patterns of change in reproductive hormones by chronological 
age according to menopausal stages (premenopause, perimenopause and postmenopause); these models were 
fitted with an interaction term between the menopausal stages and chronological age.
Results
Women included in the analysis were aged 37–61 years at the first assessment and 43–66 years at the last assess-
ment. Mean (SD) age of menopause was 49.9 (3.7) years. The correlation between reproductive and chronologi-
cal age was r = 0.63. Characteristics of the sample are presented in Tables 1 and 2. Overall, 50% of the women 
were normal weight, 55% were never smokers, 40% consumed no alcohol or consumed it up to 4 times/month, 
11% had experienced only one pregnancy, 70% had an age at menarche between 12 and 14 years, and 26% had 
a university degree.
Reproductive hormone patterns of change by reproductive and chronological age. For all four 
hormones, reproductive age patterns of change were a slightly better fit to the data than chronological age pat-
terns, though the best fit was the model including both reproductive and chronological age (Supplementary 
Table 3). Regression coefficients for each model are presented in Supplementary Table 4.
Figure 2A shows the patterns of change in hormone levels by reproductive age, adjusted for chronological 
age. These patterns represent average predicted population means derived from multilevel models for a woman 
aged 51 years. Both LH and FSH increased until ~ 5 and 7 years after the menopause, respectively, after which 
they decreased (Fig. 2A, Supplementary Table 5). For instance, for a woman aged 51 years who is 2 years before 
the FMP, the FSH level is about 20 mIU/ml, increasing to 67 mIU/ml 7 years after the FMP and decreasing to 
40 mIU/ml 15 years postmenopause. The rate of increase was higher for FSH, which also had a higher rate of 
decrease in later postmenopause than LH. SHBG decreased slightly until about 4 years postmenopause and 
started to increase subsequently, but changes in SHBG levels were small. AMH decreased markedly before the 
menopause and remained low thereafter. Compared to results unadjusted for age (Supplementary Figure 1), the 
shapes were overall similar, but hormone levels, especially at postmenopause, were generally lower, and FSH 
increased until ~ 9 years postmenopause, after which it decreased.
Hormone patterns of change by chronological age are shown in Fig. 2B. Both LH and FSH increased with 
age, with a higher rate of increase from about 46 years until approximately 58 years, after which they started to 
decline (Fig. 2B, Supplementary Table 6). For instance, FSH levels are, on average, 13 mIU/ml in a woman aged 
45 years, 39 mIU/ml in a woman aged 50, 77 mIU/ml in a woman aged 55, 89 mIU/ml in a woman aged 60, 
and 46 mIU/ml in a woman aged 65 years. The increase in FSH was more accentuated than in LH and so was 
its decline. SHBG levels changed little until about 55 years, after which they started to increase. AMH declined 
with age until about 48 years and reached undetectable levels thereafter.
Results for reproductive and chronological age models were similar when data were restricted at the 5th 
and 95th centiles of FMP and when only women with 3 or 4 repeated measures were analysed (Supplementary 
Table 3, Supplementary Figures 2 and 3). Results were also similar when analyses were repeated using GEE (Sup-
plementary Figure 4). LH and FSH increased with chronological age in both women excluded and included in 
the analyses, though with slightly different shapes (Supplementary Figure 5). SHBG increased with ageing in 
those excluded from the analyses, whilst little change was observed in those included. AMH levels before age 50 
were higher in those excluded from the analyses and decreased at later age than those included in the analyses. 
Women whose age at menopause was unknown were younger than those with known age at menopause, had 
lower levels of LH and FSH and higher levels of SHBG and AMH, and were more likely to be obese and to have 
lower frequency of alcohol intake and lower education (Supplementary Table 7). When analysis was performed 
by menopausal stages (Supplementary Figure 6), results were similar to those presented in our main analyses.
Associations of lifestyle and reproductive characteristics with reproductive age patterns of 
change in hormones. Figures 3A (BMI), 3B (smoking status), 3C (parity) and 3D (age at menarche) show 
the patterns of change in the four hormones by reproductive age according to the lifestyle and reproductive 
factors, adjusted for observed confounders. Average predicted values for each hormone are presented in Sup-
5
Vol.:(0123456789)
Scientific Reports |        (2020) 10:21258  | https://doi.org/10.1038/s41598-020-77871-9
www.nature.com/scientificreports/
plementary Table 8 and p-values for interactions are presented in Supplementary Table 9. Rates of increase of LH 
and FSH were inversely associated with BMI, with the lowest increase observed in obese women. For example, 
FSH increased on average 79% from the menopause to 5 years postmenopause in women with normal weight, 
whilst this increase was on average 58% in those with obesity. Patterns of change in SHBG with reproductive 
age were similar in all three BMI categories, with levels consistently lowest in obese women, highest in those 
who were normal weight and in between in women who were overweight. Obese and overweight women had 
lower rates of decrease in AMH compared to women with normal BMI. Patterns of change in LH and FSH 
with reproductive age were similar across all smoking categories, with FSH levels consistently lowest in cur-
rent smokers. Current and former smokers had lower rates of changes in SHBG than never smokers, as well as 
lower levels throughout reproductive age. Rates of decrease in AMH were higher in current smokers, followed 
by former smokers, compared to women who never smoked, and AMH levels before menopause followed the 
same pattern. Patterns of change in the reproductive hormones did not differ by alcohol intake, but women who 
had a higher frequency of alcohol intake had higher levels of FSH from 2 years after the menopause, lower levels 
of SHBG throughout reproductive age, and higher levels of AMH before the menopause than those with lower 
alcohol intake frequency (Supplementary Figure 7, Supplementary Table 8).
Patterns of change in LH and FSH with reproductive age did not differ by parity, but women who had 4 or 
more pregnancies had lower levels of these hormones from 6 years postmenopause. There was an association 
Table 1.  Distribution of menopausal stage, age, body mass index (BMI) and reproductive hormones at each 
clinic (N = 1,608 women). AMH: Anti-Mullerian hormone; BMI: body mass index; FSH: follicle-stimulating 
hormone; LH: luteinizing hormone; SHBG: sex hormone binding globulin. a Estimates not calculated for cells 
with less than 5 individuals.
1st assessment 2nd assessment 3rd assessment 4th assessment
N = 1,321 N = 875 N = 945 N = 896
N (%) N (%) N (%) N (%)
Menopausal stage
Premenopause 281 (21.3) 0 0 0
Perimenopause 493 (37.3) 322 (36.8) 167 (17.7) 4 (0.4)
Postmenopause 547 (41.4) 553 (63.2) 778 (82.3) 892 (99.6)
Age (years): mean (SD)
All 51.0 (4.0) 53.6 (3.9) 54.8 (3.8) 56.0 (3.6)
Premenopause 48.3 (3.2) – – –
Perimenopause 49.6 (3.3) 51.1 (3.3) 51.8 (3.5) a
Postmenopause 53.6 (3.4) 55.0 (3.5) 55.5 (3.5) 56.1 (3.5)
BMI (kg/m2): mean (SD)
All 25.8 (4.7) 25.7 (4.6) 25.6 (4.8) 25.8 (5.0)
Premenopause 25.8 (4.8) – – –
Perimenopause 25.6 (4.6) 26.2 (4.9) 26.5 (5.3) a
Postmenopause 25.9 (4.8) 25.5 (4.4) 25.4 (4.6) 25.6 (4.8)
LH (mIU/ml): median (IQR)
All 30.7 (12.6; 44.8) 37.3 (28.2; 46.9) 40.1 (31.8; 50.2) 37.3 (30.2; 46.2)
Premenopause 10.2 (5.5; 24.9) – – –
Perimenopause 24.9 (8.7; 42.2) 32.8 (17.8; 43.2) 39.5 (29.7; 50.3) a
Postmenopause 40.3 (30.9; 49.3) 39.2 (31.5; 48.8) 40.3 (32.3; 49.6) 37.0 (30.5; 46.2)
FSH (mIU/ml): median (IQR)
All 53.3 (14.2; 81.0) 69.8 (48.4; 91.2) 83.9 (65.5; 104.1) 82.2 (65.4; 101.4)
Premenopause 11.9 (5.7; 29.3) – – –
Perimenopause 33.4 (9.9; 64.7) 50.0 (26.4; 73.2) 72.3 (48.5; 94.9) a
Postmenopause 78.4 (59.8; 100.9) 77.6 (62.0; 97.0) 85.5 (68.4; 106.5) 82.7 (66.6; 101.7)
SHBG (nmol/L): median (IQR)
All 63.1 (45.4; 86.8) 64.5 (47.9; 86.6) 71.4 (51.7; 94.4) 66.8 (47.4; 89.9)
Premenopause 63.5 (48.3; 88.8) – – –
Perimenopause 67.8 (49.5; 88.8) 63.4 (45.0; 88.3) 68.8 (49.0; 91.2) a
Postmenopause 59.9 (42.0; 81.5) 64.7 (48.8; 85.0) 71.7 (51.7; 95.0) 66.9 (47.5; 90.0)
AMH (ng/ml): median (IQR)
All 0.01 (0.01; 0.04) 0.01 (0.01; 0.01) 0.01 (0.01; 0.01) 0.01 (0.01; 0.01)
Premenopause 0.06 (0.01; 0.20) – – –
Perimenopause 0.01 (0.01; 0.07) 0.01 (0.01; 0.02) 0.01 (0.01; 0.01) a
Postmenopause 0.01 (0.01; 0.01) 0.01 (0.01; 0.01) 0.01 (0.01; 0.01) 0.01 (0.01; 0.01)
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between parity and SHBG patterns of change, such that in women with more than 1 pregnancy there was a 
sharper decrease before the FMP and then a plateau or slight increase after the FMP in comparison to women 
who had experienced only one pregnancy, in whom there was little decrease before the menopause and a steeper 
increase after. There were some differences in AMH decline and levels prior to the FMP, with slower rate of 
decline and lower mean levels in women with 2–3 pregnancies than women with 1 or 4 or more pregnancies. 
Patterns of change in reproductive hormones did not notably differ by age of menarche, but levels of LH and 
FSH were lower before the menopause and from about 8–10 years postmenopause in women with late menarche 
compared to women with average age at menarche.
Results were similar when analyses were performed only in women with complete information on risk factors 
and confounders (Supplementary Table 9, Supplementary Figure 8A–E).
Associations of age at menopause with chronological age patterns of change in hor-
mones. Figure 4 shows the patterns of change in the four hormones by reproductive age according to the age 
at menopause (in quintiles). Women with earlier age of menopause had lower levels of LH and FSH until about 
6 years postmenopause and higher levels thereafter, and the decline in these hormones was later than in those 
with average age of menopause (50 years). Those with later age at menopause had lower postmenopausal levels of 
LH and FSH and these hormones started to decline earlier than in those with average age of menopause. Women 
who experienced the menopause at later age had higher increase in SHBG from about 8 years after the FMP, and 
AMH levels and decline were lower than observed for those with average age of menopause. Those with earlier 
age at menopause had the highest levels of AMH about 4 years before the FMP, and the decline in this hormone 
was slightly later than in those with menopause at on average 50 years.
Discussion
We have shown that both reproductive and chronological age are associated with patterns of change in LH, FSH, 
SHBG and AMH in mid-life in women and that BMI, smoking and parity are associated with the patterns of 
one or more of these hormones. These findings, if replicated, suggest that any exploration of the role of change 
in reproductive hormones around the time of the menopause with later adverse health outcomes must control 
for both reproductive and chronological age, and consider adjusting for BMI, smoking and parity (depending 
on the likelihood of these factors influencing the outcome of interest).
Consistent with our findings, previous studies with longitudinal data have shown that levels of LH and FSH 
increase with reproductive and chronological age at least up to the early postmenopause, and that postmenopausal 
Table 2.  Distribution of lifestyle and reproductive risk factors, and educational achievement (N = 1,608). 
A-level: advanced level; BMI: body mass index; CSE: certificate of secondary education; O-level: ordinary level. 
a 26 women (1.6%) had BMI < 18.5 kg/m2 and were included in the normal BMI category.
N (%)





Never smoker 803 (54.6)
Former smoker 520 (35.3)
Current smoker 149 (10.1)
Alcohol intake frequency
Never or less than 4 times a month 449 (40.5)
2 to 3 times a week 367 (33.1)







Early (≤ 11 years) 240 (16.2)
Average (12–14 years) 1,039 (70.0)
Late (≥ 15 years) 204 (13.8)
Educational achievement
CSE/vocational degree/O-level 637 (42.3)
A-level 475 (31.6)
University degree 393 (26.1)
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levels of these hormones remain higher than premenopausal  levels8–10,25,37. However, across our and other studies, 
there is variation in whether, after a period of increase, levels then appear to remain  stable8–10 or  decline13,38; if 
there is a decline, the age at which this occurs seems to vary. Three previous studies reported that the increase 
in FSH stabilised after 2 years  postmenopause8–10; two of those studies included fewer than 650 women and the 
largest one had 1,215 women, and all had more repeat measures than our study (varying from average 5.3 to 9.1 
measures per women). An additional two studies (a Swedish study of 160 women with an average of 16 repeat 
 measures13, and a US study of 856 women with up to 12 follow-up visits)38 showed postmenopausal declines 
in LH and FSH, as in our study, with these declines beginning earlier, around 1–4 years postmenopause. The 
differences between studies in stabilise/decline and when the decline occurs is likely to be due to differences 
in length of follow-up, number of repeats, potential methodological differences relating to assays, and possibly 
distribution of other characteristics, such as BMI, smoking and parity. The decline in both LH and FSH might 
be due to pituitary desensitization in the positive feedback of oestrogen, with a relative hypothalamic-pituitary 
insensitivity to oestrogen in ageing  women39. Increased adiposity might also play a role, as observed in this 
and other  studies26,28. Our study has the longest postmenopausal follow-up to date, and the mechanisms that 
explain reproductive hormone changes in a longer postmenopausal period are not known and require further 
exploration.
Although changes in SHBG were small, we observed a slight decrease up to 4 years postmenopause, followed 
by an increase small in magnitude. Differently from our study, three of the four longitudinal studies that have 
assessed patterns of change in SHBG reported decreases after the menopause, with no increase  thereafter11,13,40. 
One showed a marked increase (of 81%) across the  perimenopause14. Those studies were smaller (all including 
fewer than 450 women) and had shorter follow-up periods (up to 8 years postmenopause). Our findings cor-
roborate results from cross-sectional studies to some extent, in which SHBG has been shown to be inversely 
associated with age between 20 and 60 years, after which it is higher at older  ages21,41,42. The marked decline, to 
undetectable levels, in AMH before the menopause has been consistently shown in longitudinal  studies15,16,22,43.
The 2011 STRAW + 10 updated previous reproductive categories based on a detailed review of evidence and 
expert discussion, with a particular focus on evidence of the critical changes in hypothalamic-pituitary-ovarian 
function that occur before and after the  FMP33. LH and FSH are central to this axis, with their secretion from the 
Figure 2.  Average predicted population means (95% CI) for reproductive hormones across reproductive age 
(A) and chronological age (B). Dashed vertical line corresponds to menopause (A) or average age of menopause 
in the study (B).
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Figure 3.  Association of lifestyle and reproductive factors with mean hormone levels at different reproductive 
ages. In these analyses, all covariates used in the adjustment were set to the mean value or the reference category: 
age (51 years), education (CSE/Vocational degree/O-level), body mass index (< 25 kg/m2), smoking status (never 
smoker), alcohol intake (never or less than 4 times a month), age at menarche (13 years).
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pituitary and circulating levels controlled by feedback loops involving gonadotropin-releasing hormone from the 
hypothalamus and, in women, oestrogen and progesterone levels from the ovaries. The workshop concluded that 
“although smoking and BMI influence [reproductive] hormonal levels and the timing of [menopausal] transi-
tion, these factors do not alter the trajectory of change in bleeding patterns or hormonal levels with reproductive 
aging. Therefore, the STRAW + 10 staging system is applicable to women regardless of age, demographic, BMI, 
or lifestyle characteristics”13. However, our results and those from other longitudinal studies (summarised in 
Supplementary Table 1) challenge these conclusions, showing that lifestyle and reproductive factors are not only 
associated with hormone levels but also with different patterns of reproductive age-related changes. In light of 
major changes in these risk factors over the last decades, such as decrease in smoking prevalence in mid-aged 
women in high-income countries and increase in overweight/obesity44, it may be important to take these into 
consideration when defining reproductive categories based on STRAW criteria. If our results are replicated, 
future versions of these categories should also consider whether category definitions should vary between women 
with differing levels of BMI, smoking and parity. Although differences in hormone changes observed by par-
ity categories could be explained by age at pregnancy, post hoc analysis including age at first pregnancy in the 
adjustment did not change the results (Supplementary Figure 9).
Strengths and limitations. This is the largest prospective study to date with measures of four reproduc-
tive hormones that span the late reproductive period and postmenopause. The average 5-year follow-up period 
with up to four repeat measures in women of different baseline ages allowed the description of hormone patterns 
of change from 4 years before to 16 years after the menopause, a longer postmenopausal period than described 
in previous studies. We were also able to explore the influence of lifestyle and reproductive factors on the hor-
monal patterns of change by reproductive ageing, adjusting for observed confounders, which very few previous 
longitudinal studies have done.
We used multilevel models, which allow all women with at least one measure of the hormone levels to be 
included in the analysis under the MAR assumption, i.e. associations do not differ in those who have fewer 
repeat measures. It is not possible to test this assumption directly. Sensitivity analysis of women who had 3 or 4 
repeat measures showed similar results to those with at least one repeat measure, and similar results were also 
observed using GEE, providing support that this assumption is not notably violated as we would expect results 
to be different if data were MCAR.
We restricted the follow-up in the second, third and fourth clinic assessments to women who were pre- or 
perimenopausal and aged 40 years or older at the first assessment, so that they were likely to transition through 
the menopause. This may have introduced some selection bias. However, given the focus of this paper is on 
Figure 4.  Association of age at menopause with mean hormone levels by reproductive age. Quintiles of age at 
menopause [mean age (SD)]: Q1: 44.2 (2.9), Q2: 48.4 (0.6), Q3: 50.1 (0.5), Q4: 52.2 (0.7), Q5: 54.8 (1.5).
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changes in hormones across the menopausal transition, had these women been included, they were unlikely to 
have contributed to the results presented here. The mean reproductive age of this excluded group would have 
moved closer to their future FMP over the three assessments, however, due to their young age, most are unlikely 
to have started to experience menopause-related changes in their sex hormones. Furthermore, the selection by 
age means that bias is unlikely because age, the source of selection (missingness), is included in all of our analysis 
models, which means that the MAR assumption of multilevel models is unlikely to be violated.
We used fractional polynomials to model the non-linear associations; although these can be influenced by 
outliers, analyses excluding women in the bottom and top 5% of the distribution of FMP showed similar results to 
the analysis including all women. We compared models of hormone patterns by reproductive and chronological 
age (separately and combined) and showed that models with both reproductive and chronological age were the 
best fit of our hormonal data, suggesting the importance of the menopause transition in the patterns of these 
hormones. We only included women who are known to have gone through a natural menopause, and excluded 
those whose age at menopause was unknown. This could have introduced selection bias, which might be reflected 
by the lower average age of menopause than found in other  studies45. However, the mean age of menopause was 
similar to that observed in a meta-analysis of 17 studies in seven high-income countries, including the UK (mean 
age 50.2, SD 4.4)46. We performed sensitivity analysis including women whose age at menopause was unknown 
and the results, though slightly different than the main analysis, followed what it would be expected given the 
younger age of those with unknown menopause status compared to those with known age at menopause. There-
fore, it is unlikely that selection bias have substantially influenced our results.
We did not have data on oestradiol. Previous studies show (as expected biologically) that oestradiol mir-
rors FSH, such that as FSH increases between 2-years before and 2-years after the FMP, oestradiol decreases, 
with the two subsequently stabilizing at high and low levels,  respectively9,10,12,13. Our study is predominantly of 
White European origin women, and previous studies have shown ethnic differences in reproductive hormone 
 levels18,26,28. Whilst ethnic differences in mean levels do not mean that patterns of change with reproductive and 
chronological age, or associations of lifestyle and reproductive factors with these patterns, will differ by ethnicity, 
it is possible that our findings might not generalise to women of other race/ethnic groups. As our study recruited 
women during an index pregnancy and only followed those with a live birth from that pregnancy, all participants 
had at least one live birth and we cannot assume that our findings would generalise to women with no previous 
pregnancies or live births. In particular, the association of parity with changes in reproductive hormones may 
differ in studies that also include nulliparous women. As women without an observed natural menopause were 
excluded, our results might not generalise to all women. However, the results for patterns of change in hormones 
by chronological age were broadly similar in the whole sample of women compared to when restricted to women 
who had gone through the menopause. The modest differences in patterns of change, mostly seen with SHBG, 
may be related to differences in ages between those included in our main analyses and the whole cohort, with 
those who have gone through the menopause being older on average than the whole cohort.
Conclusions
Our results add to the relatively sparse literature of studies with repeat measurements of reproductive hormones 
(see Supplementary Table 1) by exploring the relation of both chronological and reproductive age, and of life-
style and reproductive factors with hormone levels. Our, and previous studies, show increases in LH and FSH 
with reproductive age, with levels remaining higher in postmenopause compared to premenopause, and that 
AMH declines markedly just before the menopause to undetectable levels. Novel findings from our study are 
the importance of both reproductive and chronological age to the reproductive hormone patterns of change, 
and the associations of BMI, smoking and parity with these patterns. Future studies of the associations of these 
hormones with health outcomes should consider potential confounding by chronological and reproductive age, 
as well as BMI, smoking and parity, and the current STRAW criteria for reproductive stage categories, which 
assume that lifestyle and reproductive factors do not influence hormone patterns, may need to be reconsidered.
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